T. Rowe Price Investment Management
NMRA icon

T. Rowe Price Investment Management’s Neumora Therapeutics NMRA Stock Holding History

T. Rowe Price Investment Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,938,100
Closed -$3.53M – 940
2025
Q3 		$3.53M Sell
1,938,100
-164,929
-8% -$267K ﹤0.01% 586
2025
Q2 		$1.54M Hold
2,103,029
– – ﹤0.01% 613
2025
Q1 		$2.1M Sell
2,103,029
-2,899,770
-58% -$4.97M ﹤0.01% 602
2024
Q4 		$53M Sell
5,002,799
-225,534
-4% -$2.7M 0.03% 402
2024
Q3 		$69.1M Buy
5,228,333
+127,237
+2% +$1.48M 0.04% 356
2024
Q2 		$50.1M Buy
5,101,096
+1,517,092
+42% +$15.7M 0.03% 387
2024
Q1 		$49.3M Buy
+3,584,004
New +$57.9M 0.03% 398

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

T. Rowe Price Investment Management's NMRA Position: Q4 2025 in Review

T. Rowe Price Investment Management sold out of Neumora Therapeutics (NMRA) in Q4 2025, closing a stake of 1,938,100 shares — an estimated $3.53M sold.

T. Rowe Price Investment Management first reported a position in NMRA in Q1 2024 and held it in 7 quarters. The position peaked at $69.1M in Q3 2024. 102 funds tracked by Wall St. Rank hold NMRA as of Q4 2025.

  • T. Rowe Price Investment Management reported no remaining Neumora Therapeutics position as of Q4 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,938,100 Neumora Therapeutics shares in Q4 2025, an estimated $3.53M.
  • T. Rowe Price Investment Management first reported a position in Neumora Therapeutics in Q1 2024 and held it in 7 quarters.
  • T. Rowe Price Investment Management's Neumora Therapeutics position peaked at $69.1M in Q3 2024.
  • 102 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.